Pharmaceuticals, Biotechnology and Life Sciences
Category: My Pharmaceutical
The anti-vaxxers who voted for Trump are now watching him mandate vaccines
The movement that spent years insisting vaccines were dangerous, unnecessary, and a tool of government overreach just got an unusual…
Who decides in the EU?
Out of five Croatians in Brussels, roughly one in five Croatians decided who would speak for the other four in…
Beyond the transplant list: the pediatric cardiomyopathy pipeline finally has momentum
Dilated cardiomyopathy (DCM) is the most common form of cardiomyopathy in children and the leading reason kids end up on…
BioCardia’s cell therapy may help the failing heart stop working against itself
Phase III echocardiography data presented at THT 2026 suggest a targeted cellular approach may do what drugs alone cannot for a specific population of ischemic heart failure patients
Light instead of antibiotics: Ondine’s Phase 3 trial is weeks away from results that could reshape surgical infection prevention
A five-minute pre-surgical procedure using light is about to face its biggest test — and the clinical trial metrics, according to the company, are unusually clean.
AI and job cuts: What the block layoffs signal for pharma and beyond
In the past few months, the corporate world has seen a surge in workforce reductions that are explicitly tied to artificial intelligence (AI) and automation — not just general cost-cutting. The biggest recent example comes from fintech firm Block Inc., which announced plans to cut over 4,000 jobs — roughly 40 % of its workforce — as AI tools reshape how it builds and runs its business, according to multiple news reports. What about pharma?
The ADC arms race: payload power vs targeting precision
Over the past decade, antibody-drug conjugates (ADCs) have emerged as a high-impact class of cancer therapies, blending the selectivity of antibodies with the potency of cytotoxic payloads. But as the modality matures, a structural tension is becoming clear: should innovation focus on chemical escalation of payloads and linkers, or on biological precision of target engagement?
Bispecific ADCs: are dual-target ‘AND-Gate’ designs the future of tumour selectivity?
Antibody-drug conjugates (ADCs) continue to evolve as one of the most promising approaches in targeted cancer therapy, yet the fundamental…
Women urged to put breast density knowledge at the top of their Christmas list
Micrima, a Bristol-based health tech company, is urging women to give themselves the gift of prioritising knowledge of their breast…
Just a note about how AI is changing journalism
By Dino MustafićJust a note about how AI is changing journalism